Perspective Therapeutics Says First Patient Dosed In New Cohort Of Phase 1/2a Trial Evaluating The Safety Of [212Pb]VMT01

Author: Benzinga Newsdesk | September 15, 2025 06:08am

• First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab
• [212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened

SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with previously treated, histologically confirmed metastatic melanoma and positive melanocortin 1 receptor (MC1R) imaging scans.

Patients in this cohort are receiving [212Pb]VMT01 at 3.0 mCi in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb as Opdivo®. Additionally, the [212Pb]VMT01 3.0 mCi monotherapy cohort reopened for enrollment. The Safety Monitoring Committee (SMC) recommended evaluating [212Pb]VMT01 at a higher dose based on its review of five patients dosed with [212Pb]VMT01 1.5 mCi monotherapy and two patients dosed with [212Pb]VMT01 at 1.5 mCi together with nivolumab.

Posted In: CATX